This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Gilead HIV Pill Fails

Shares of Gilead Sciences (GILD - Get Report) dropped in after-hours trading Tuesday after the company failed in a first attempt to create a new HIV pill with Bristol-Myers Squibb (BMY - Get Report).

After markets had closed, Gilead said it would reformulate the pill, which combines its Truvada HIV pill with Bristol-Myers Squibb's Sustiva HIV medication. Assuming the reformulation works, Gilead said it believed it could submit on application for the once-a-day combination drug to the Food and Drug Administration by year-end.

Gilead's stock dropped $1.80, or 4.6%, to $37.50 in after-hours trading after having lost a penny in regular trading. Shares of Bristol-Myers Squibb lost 17 cents in regular trading to close at $25.69.

The companies established a U.S. joint venture last December to develop a Truvada-Sustiva pill. Gilead said the first formulation failed because the Sustiva levels measured in patients' blood were too low.

Because blood levels of Sustiva in the combination pill were less than those of Sustiva alone, the experimental pill failed to achieve bioequivalence. The companies must meet this standard to convince the FDA to approve the new pill.

The companies say a once-a-day combination pill "may help simplify HIV therapy." Gilead's Truvada is, itself, a once-a-day combination drug containing Emtriva and Viread.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG
BMY $64.84 0.00%
GILD $118.87 0.00%
AAPL $114.64 0.00%
FB $94.06 0.00%
GOOG $629.25 0.00%

Markets

Chart of I:DJI
DOW 17,550.69 -47.51 -0.27%
S&P 500 2,093.32 -4.72 -0.22%
NASDAQ 5,105.5460 -9.8360 -0.19%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs